CD44 and neoplasm: Harrison et al. (2010) reported that anoikis resistant cells from breast cancer cell lines and primary human tumours were mainly ESA+CD44+CD24low with self-renewal and tumorigenic properties in vitro and in vivo, therefore classified as breast CSCs [79].